U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07716865) titled 'Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)' on March 18.
Brief Summary: The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA). In the study participants receive increasing dose or active treatment (250 mg vs 500mg vs 750 mg) or matched placebo in the form of tablets BID.
Study Start Date: April 03, 2024
Study Type: INTERVENTIONAL
Condition:
Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
Hemorrhage Brain
Hemorrhage Cerebral
Intervention:
DRUG: NACA
250...